Cerebrolysin — Porcine-Brain Neuropeptide Preparation

Discovery and Origin

Cerebrolysin was developed in Austria during the nineteen-fifties and nineteen-seventies by the pharmaceutical group then known as Nycomed, now operating as EVER Pharma GmbH, headquartered in Unterach am Attersee. The foundational insight was that the mammalian brain contains a wealth of biologically active peptide fragments — breakdown products of larger proteins that retain growth-factor-like and neuroprotective properties — and that these could be extracted, standardised, and administered systemically to exert therapeutic effects on injured or degenerating neural tissue.

The manufacturing process begins with porcine cerebral cortex tissue, which undergoes controlled enzymatic hydrolysis under tightly regulated conditions. The resulting hydrolysate is fractionated and ultrafiltered to remove high-molecular-weight proteins and lipids, yielding a clear, amber-coloured solution whose active fraction consists of peptide molecules all falling below ten kilodaltons in molecular mass. This size cutoff is pharmacologically significant: peptides in this range are capable of crossing the blood-brain barrier via adsorptive transcytosis, allowing systemic intravenous or intramuscular administration to deliver active material directly to the central nervous system. The final composition of the licensed product is approximately twenty-five percent neuropeptides by dry mass, with the remaining seventy-five percent comprising free amino acids that serve as metabolic precursors to neurotransmitters and structural proteins.

Over subsequent decades the product accumulated clinical trial data across a broad range of neurological indications — ischaemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease — leading to regulatory approval in more than forty countries across Europe, Asia, and Latin America. EVER Pharma continues to hold the originator marketing authorisation.

Mechanism of Action

The pharmacology of Cerebrolysin cannot be reduced to a single receptor interaction. Its constituent peptide fraction acts through several convergent pathways that together reproduce many of the downstream effects of endogenous neurotrophic factors.

Neurotrophic-Factor Mimicry. The best-characterised mechanism is the mimicry of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) signalling. Specific peptide constituents of the Cerebrolysin fraction have been shown to activate TrkA and TrkB receptor pathways in neuronal cell cultures, promoting neuronal survival, axonal sprouting, and synaptic density. This activity is thought to be responsible for the post-stroke functional recovery and cognitive stabilisation observed in clinical trials — effects that mirror, at a reduced magnitude, those of direct exogenous BDNF or NGF administration, but without the pharmacokinetic limitations that make the full-length growth factors themselves clinically impractical.

Neuroprotection in Ischaemic Models. In rodent and primate models of focal cerebral ischaemia, Cerebrolysin administered within the first hours following occlusion reduces infarct volume, attenuates glutamate-mediated excitotoxicity, suppresses caspase-dependent apoptotic cascades, and blunts the post-ischaemic inflammatory response by reducing IL-one-beta and TNF-alpha expression in peri-infarct tissue. The timing-dependent nature of this benefit — with the greatest reduction in lesion volume seen with early administration — has informed the acute-treatment protocols explored in the major Phase III trials.

Anti-Amyloid and Alzheimer's Pathology Research. A distinct and growing body of preclinical evidence links Cerebrolysin to modulation of amyloid-beta processing. In transgenic Alzheimer's disease mouse models, treatment has been associated with reduced plaque burden and improved performance on spatial memory tasks. Mechanistically this appears to involve upregulation of the alpha-secretase pathway relative to amyloidogenic beta-secretase processing, as well as enhancement of amyloid-beta clearance via microglial activation. These findings have supported clinical trials in mild-to-moderate Alzheimer's disease.

Synaptic Plasticity and Neurogenesis. At a cellular level, Cerebrolysin enhances hippocampal neurogenesis in adult rodents and increases dendritic branching and spine density in cortical neurons, effects consistent with its BDNF-mimetic properties. These structural changes are hypothesised to contribute to the sustained cognitive improvements reported in longer treatment courses.

Researched Applications

Post-Stroke Motor and Cognitive Recovery — CASTA Trial. The most influential controlled trial of Cerebrolysin in acute stroke is the CASTA (Cerebrolysin and Recovery After Stroke) Phase III study led by Wolf-Dieter Heiss and published in two thousand and twelve [PMID:22282888]. The trial enrolled patients across multiple centres in Asia with acute ischaemic stroke and randomised them to thirty millilitres of Cerebrolysin daily intravenously for ten days versus placebo. The primary endpoint — modified Rankin Scale at ninety days — did not reach statistical significance in the full intention-to-treat population, but pre-specified subgroup analyses showed a significant benefit in patients with moderate-to-severe baseline deficits, a finding that has shaped current clinical thinking about patient selection. Safety outcomes, including rates of haemorrhagic transformation, were comparable between arms, a relevant finding given earlier theoretical concerns about Cerebrolysin's effect on vascular permeability [Bornstein et al.].

Stroke Rehabilitation — CARS Trial. The CARS (Cerebrolysin and Recovery from Stroke) trial, led by Dafin Muresanu and published in two thousand and sixteen [PMID:26564102], examined Cerebrolysin as an adjunct to early physical rehabilitation in the subacute post-stroke period. Patients receiving Cerebrolysin in addition to standard physiotherapy showed significantly greater improvements on the Barthel Index and NIH Stroke Scale compared to rehabilitation plus placebo, with the differential particularly pronounced at the three-month assessment. The CARS findings contributed to the inclusion of Cerebrolysin in stroke rehabilitation guidelines in several Eastern European jurisdictions.

Alzheimer's Disease — Mild to Moderate. Alvarez and colleagues conducted a double-blind, placebo-controlled trial of Cerebrolysin in mild-to-moderate Alzheimer's disease [PMID:17010401] and demonstrated significant improvements on both the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Clinical Global Impression scale following a four-week treatment course. A Cochrane-style review by Plosker and Gauthier synthesised the Alzheimer's evidence base and concluded that the available data, while limited by heterogeneous trial designs, are consistent with a clinically meaningful cognitive benefit in this population, with an acceptable tolerability profile.

Traumatic Brain Injury and Vascular Dementia. Smaller controlled studies and observational series support utility in post-traumatic cognitive impairment and vascular dementia, though these indications have less Phase III trial support than stroke and Alzheimer's disease. The regulatory approvals in Russia and China include vascular dementia as a licensed indication.

Dosing Protocols (Research Context)

Standard dosing in the clinical literature for post-stroke and cognitive indications is five to ten millilitres administered intramuscularly or ten to thirty millilitres administered intravenously once daily for ten to twenty consecutive days. The intravenous route, when used, requires dilution in one hundred to two hundred millilitres of normal saline and slow infusion over sixty minutes; bolus intravenous injection is not appropriate.

The most commonly referenced research protocols are:

• Acute stroke / intensive cognitive rehabilitation: twenty to thirty millilitres intravenously once daily, diluted in normal saline, infused over sixty minutes, for ten to twenty days
• Maintenance or outpatient cognitive support: five to ten millilitres intramuscularly once daily for ten to twenty days, repeated in cycles of two to four times per year
• Alzheimer's disease trials: typically ten to thirty millilitres IV over twenty-eight-day treatment courses

The preparation is used as supplied and does not require further reconstitution. Cycles are separated by rest periods of at least one to two months in most published protocols. No dose escalation paradigm has been established; the relationship between dose and clinical effect is not clearly linear across the studied range.

Safety Profile

Cerebrolysin has a well-characterised tolerability record accumulated across decades of clinical use in approved territories. The most commonly reported adverse effects are mild injection-site reactions with the intramuscular route — local erythema, transient discomfort, and occasional induration — which are largely technique-dependent and resolve without intervention.

Systemic adverse effects at recommended doses are infrequent. Rare reports of headache, dizziness, and nausea, predominantly at higher intravenous doses, have been recorded in clinical trial databases. Hypersensitivity reactions are theoretically possible given the biological origin of the product; patients with known porcine protein hypersensitivity should not receive the preparation. No hepatotoxic, nephrotoxic, or haematological signals have emerged in the controlled trial literature.

The theoretical concern raised in early post-marketing experience about haemorrhagic transformation risk in acute stroke — relevant because many Cerebrolysin patients are also anticoagulated or on antiplatelet therapy — was systematically evaluated in the CASTA trial by Bornstein and colleagues. No significant difference in symptomatic haemorrhagic transformation rates between Cerebrolysin and placebo was identified, providing reasonable reassurance at the standard doses studied.

Cerebrolysin is not genotoxic or mutagenic in standard battery testing. Reproductive and developmental toxicology data are limited, and use in pregnancy is not recommended. The product should be stored protected from light at room temperature and not frozen; freezing causes visible precipitation and renders the preparation unusable.

UK Regulatory Status

Cerebrolysin does not hold a marketing authorisation in the United Kingdom. It is not a controlled drug under the Misuse of Drugs Act and is not captured by the Psychoactive Substances Act, but it is an unlicensed medicinal product, which means its supply, importation for personal use, or administration in a clinical setting is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

The operative UK pathway for lawful access to Cerebrolysin is the MHRA Special Authorisation (also referred to as a Specials import licence). A licensed medical practitioner must apply to the MHRA for authority to import a specific quantity of the product for a named patient, providing clinical justification for the unlicensed use and confirming that no licensed equivalent is available. The application process is documented in MHRA guidance under its Specials and Imports regulatory framework. Without such authorisation, importation for human use carries regulatory risk, including the possibility of border seizure by HMRC and MHRA on grounds of unlicensed medicinal importation. Supply by commercial entities to UK consumers without a Specials licence is an offence under the Human Medicines Regulations. For laboratory and research purposes only, the product may be procured through specialist research chemical suppliers operating under the research-use exemption.

Clinicians in NHS or private practice wishing to use Cerebrolysin in a post-stroke or dementia rehabilitation context should initiate the Named Patient Special Import process through a registered Specials importer, of which several MHRA-licensed firms operate in the UK.

Reconstitution and Preparation

Unlike most peptide research compounds that arrive as lyophilised powder requiring reconstitution, Cerebrolysin is supplied exclusively as a pre-formulated aqueous solution. It is not available in powder form. The licensed product arrives in sealed glass ampoules of one, two, five, ten, or twenty millilitres, containing the hydrolysate at its standardised concentration, ready for direct use.

No reconstitution step is required. For intramuscular administration, the contents of the appropriate ampoule are drawn into a sterile syringe using aseptic technique and injected into the gluteal or lateral thigh musculature. For intravenous administration, the contents are transferred aseptically into a compatible infusion bag containing one hundred to two hundred millilitres of sterile normal saline (sodium chloride at nine grams per litre) and administered via slow intravenous drip over a minimum of sixty minutes. The preparation should not be mixed in the same infusion bag as other medications; co-administration compatibility has not been systematically characterised.

Ampoules should be inspected before use; the solution should be clear to slightly amber and free of visible particulate matter. Any ampoule exhibiting cloudiness, precipitate, or discolouration should be discarded. Opened ampoules must be used immediately and not stored; the product contains no preservative and is intended for single-dose use per ampoule.

Frequently Asked Questions

Is Cerebrolysin derived from animal tissue? Yes. The active ingredient is produced by controlled enzymatic hydrolysis of porcine (pig) cerebral cortex. This is relevant both for patients with religious or ethical objections to porcine-derived products and for any consideration of prion-related theoretical risk, though EVER Pharma's quality system includes extensive sourcing and processing controls to address the latter, and no prion transmission event has been attributed to the product in its multi-decade history.

Can Cerebrolysin be used alongside Semax? These two preparations are frequently combined in Eastern European clinical practice and research settings. They have complementary mechanisms — Cerebrolysin acts primarily through its neuropeptide fraction's neurotrophic-factor mimicry, while Semax upregulates endogenous BDNF and NGF gene expression. No controlled trial has formally evaluated the combination, and the interaction evidence base is limited to case series and observational reports. No pharmacokinetic incompatibility has been identified.

How long until effects are noticeable? In acute stroke trials, statistically detectable differences in neurological scores between Cerebrolysin and placebo groups emerged at assessment points from seven to thirty days. In Alzheimer's disease trials, cognitive scale improvements were detectable at four weeks. In healthy individuals using Cerebrolysin for cognitive enhancement outside a disease context, subjective effects — described variously as improved focus, mental clarity, and verbal fluency — are typically reported from the second half of a ten-day course onwards, though the individual response is highly variable.

Is the injectable route the only option? Yes. The BBB-permeable neuropeptide fraction is too large for meaningful oral absorption and would be degraded by gastrointestinal proteases before reaching systemic circulation. No oral, intranasal, or transdermal formulation of Cerebrolysin has been clinically validated. Intramuscular and intravenous routes are the only delivery methods with a controlled evidence base.

---

Explore Related Stacks

• Cerebrolysin + Semax Cognitive Stack

Source research-grade Cerebrolysin

Cerebrolysin — Porcine-Brain Neuropeptide Preparation is sold for laboratory and in vitro research use only. UK regulatory status: Approved as a medicinal product in 40+ jurisdictions including Austria, Russia, China, Czech Republic, Mexico (post-stroke + cognitive indications). NOT licensed in UK or US — MHRA Special Authorisation required for UK import. Laboratory research use only outside approved territories..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk